Standard InChI: InChI=1S/C46H57FN4O9/c1-8-42(55)22-27-23-45(40(53)58-6,36-29(13-17-50(24-27)25-42)30-19-28(47)11-12-33(30)48-36)32-20-31-34(21-35(32)57-5)49(4)38-44(31)15-18-51-16-10-14-43(9-2,37(44)51)39(60-26(3)52)46(38,56)41(54)59-7/h10-12,14,19-21,27,37-39,48,55-56H,8-9,13,15-18,22-25H2,1-7H3/t27-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
1.Gotoh H, Duncan KK, Robertson WM, Boger DL.. (2011) 10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids., 2 (12):[PMID:22247789][10.1021/ml200236a]
2.Leggans EK, Duncan KK, Barker TJ, Schleicher KD, Boger DL.. (2013) A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives., 56 (3):[PMID:23244701][10.1021/jm3015684]
3.Lukesh JC, Carney DW, Dong H, Cross RM, Shukla V, Duncan KK, Yang S, Brody DM, Brütsch MM, Radakovic A, Boger DL.. (2017) Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance., 60 (17):[PMID:28857558][10.1021/acs.jmedchem.7b00958]
4.Radakovic A, Boger DL.. (2018) High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs., 28 (5):[PMID:29439899][10.1016/j.bmcl.2018.02.006]